OptiNose (OPTN) Projected to Post Quarterly Earnings on Thursday

Posted by Defense World Staff on Mar 13th, 2025

OptiNose (NASDAQ:OPTN – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $21.02 million for the quarter.

OptiNose Trading Up 0.4 %

NASDAQ:OPTN opened at $5.47 on Thursday. The company has a 50-day moving average price of $5.86 and a 200-day moving average price of $8.55. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50. The stock has a market cap of $55.03 million, a price-to-earnings ratio of -1.30 and a beta of -0.30.

Insider Buying and Selling at OptiNose

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on OPTN shares. Piper Sandler dropped their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. HC Wainwright lifted their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, Lake Street Capital lowered their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, January 16th.

Read Our Latest Report on OptiNose

OptiNose Company Profile

(Get Free Report)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.